Thu, Nov 20, 2014, 4:21 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Amarantus Bioscience Holdings, Inc Message Board

  • smittysghost smittysghost Nov 22, 2013 9:18 AM Flag

    "Amarantus - MANF - Diabetes"

    If anyone knows of another stock trading under a nickle that has the potential upside that AMBS offers please let me know.

    It's obvious to me that one of the N.D.A.'s that Gerald is operating under is in the field of diabetes. There has been speculation that the "big pharma" company that it is with is Novartis. The field of diabetes offers tremendous opportunities as it is the fastest growing disease in the United States.

    Is it a coincidence that Dr. Owen Garrick is on the company's advisory board?

    His background:

    Dr. Garrick joins Amarantus with over 20 years of pharmaceutical and biotechnology experience. He currently serves as the Chief Operating Officer at Bridge Clinical Research and is President of the American Medical Association Foundation. Prior to that, he was Director of Corporate Strategy and Business Development at McKesson Corporation. ]Dr. Garrick was Executive Director and Co-Head of Mergers & Acquisitions at Novartis Pharmaceuticals where he oversaw company acquisitions, hybrid equity/license rights deals, mature product divestments and venture investments in biotechnology companies Prior to Novartis, Dr. Garrick was an associate at Goldman Sachs in New York. Dr. Garrick received his MD from Yale School of Medicine and earned his MBA from Wharton School of Business. He holds an AB from Princeton University, where he has served on the national fund raising board.

    Just saying!!!

    Follow the company on Twitter: @AmarantusBio .... 8,626

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AMBS
0.079+0.002(+3.13%)3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.